About
X4 Pharmaceuticals is a fully integrated, commercial-stage biopharmaceutical company focused on driving progress for people living with rare immune disorders. The company listens to those whose challenges have been long overlooked, develops solutions to their most urgent health concerns, and delivers impact through its FDA-approved medication XOLREMDI® (mavorixafor), now commercially available in the U.S. in its first indication. X4 is also evaluating mavorixafor in additional potential indications, including an ongoing global, pivotal Phase 3 clinical trial for chronic neutropenia. Headquartered in Boston, Massachusetts, X4 Pharmaceuticals is committed to advancing innovative treatments that make a difference.
BostonBiotechnology